Duoning Biotechnology Co. Ltd. of Shanghai, has announced that the company signed an Agreement on the Transfer of the Right to Use State-owned Construction Land with the Bureau of Planning and Natural Resources of Fengxian District, Shanghai. This will be the officially setting for its global headquarters at the Biotechnology Park of Shanghai Fengxian Economic Development Zone.
Duoning will build an R&D center and a technology applications center (TAC) based on the park’s innovative vibe and clustering advantages.
The global headquarters, R&D center, and TAC are located in the heart of the Biotechnology Park, with a total planned area of 20,029.8 m2. It is planned with an office building, an R&D testing center, pilot plants, supporting utilities, etc.
The total construction area of the project will be over 40,000 m2. As a leading one-stop bioprocess solutions provider in China, the company is focused on providing comprehensive solutions for biological products from research to commercialization and continues to empower the life sciences industry with its two major businesses — bioprocess solutions and lab products & services.
After signing the agreement, Duoning will provide research institutions, CROs/CDMOs, and pharmaceutical companies with equipment, consumables, and process-related services required for biologics research and manufacture based on the established biopharmaceutical industry cluster in the park.
Meanwhile, the company will cooperate with the park to further exert the agglomeration effect, pursuing the creation of a world-class life sciences industrial belt while building a highland for China’s biopharmaceutical industry.
“In Fengxian Biotechnology Park, we will offer solutions covering both the upstream and downstream of bioprocesses to meet the needs of the biological products at all stages and explore a highly efficient industrialization model in this industry based on the zero-distance contact with outstanding talents and companies here.
I believe that with our vast experience and one-stop bioprocess solutions, we can shoulder the responsibility of relieving the ‘pain points’ of the industry. At the same time, we also look forward to working with the government and all parties in the industry to advance the development of China’s life sciences industry,” said Wang Meng, Chairman and Chief Executive Officer of Duoning.
Duoning Biotechnology Co., Ltd., of Shanghai is a leading Chinese biotechnology firm dedicated to the research and development of innovative pharmaceutical solutions. Established in 2003, Duoning became a respected provider of gene therapy-based treatments that are designed to improve patient outcomes.
Duoning’s commitment to providing safe and effective products that are available at a reasonable cost, has earned them recognition as pioneers in the field of biotechnology.
The company specializes in developing therapies with the potential to treat diseases such as cancer, cardiovascular diseases, and diabetes. Utilizing cutting-edge technology, Duoning leverages artificial intelligence and big data analysis to generate more precise diagnoses and treatment plans for patients.
Their deep understanding of molecular biology allows them to accurately design gene therapies tailored to specific illnesses or conditions.
Duoning Biotechnology Co., Ltd. of Shanghai is taking its commitment to the biopharmaceutical industry seriously and has set up a comprehensive plan for its headquarters in Fengxian District, Shanghai.
With an R&D center, technology applications center (TAC), and office building planned with over 40,000 m2 of total construction area, Duoning aims to provide research institutions, CROs/CDMOs, and pharmaceutical companies with equipment, consumables, and process-related services needed for biologics research as well as manufacture.
Chairman Wang Meng’s vision is that this will be a highly efficient industrialization model which can relieve pain points within the life sciences industry while advancing it overall in China. We look forward to seeing how Duoning’s innovative approach succeeds.
Sources: THX News, CB Insights & Duoning Biotechnology.